Orexo Liabilities 2025

Orexo Aktienanalyse

What does Orexo do?

Orexo AB is a Swedish pharmaceutical company that was founded in 1995 and is headquartered in Uppsala. The company focuses on the development of medications for the treatment of pain and addiction disorders. Business model: Orexo's business model is based on the development of innovative medications and their marketing in the global market. The company specializes in the development of medications based on opioid technology. Divisions: Orexo operates in two main business areas: Pharmaceuticals and digital therapeutics. Pharmaceuticals: In the pharmaceutical division, Orexo is primarily involved in the development of medications used in the treatment of pain and addiction disorders. Some of the best-known medications include: - Zubsolv: a medication for the treatment of opioid addiction - Abstral: a fast-acting pain medication for cancer patients - Edluar: a sleep medication for the treatment of sleep disorders Orexo's pharmaceuticals are distributed in over 60 countries worldwide and have already helped many patients alleviate their symptoms. Digital therapeutics: Orexo has expanded its business model and offers digital therapeutics - apps that contribute to improving the success of pain and addiction disorder treatment. One example is the app "Orexo Digital," which helps patients better monitor their medication and document the progress of their treatment. The app is free and can be downloaded by patients who have been prescribed medications from Orexo. History: Orexo was founded in 1995 by a team of researchers from Uppsala University. The company initially focused on the development of medications for the treatment of inflammatory diseases and allergies. In 2003, the company decided to concentrate on the development of medications in pain and addiction treatment. The first products in this area were the pain medication Abstral and the substitution medication Zubsolv. In the following years, the company grew rapidly and opened additional locations in the United States, United Kingdom, and France. Orexo works closely with key players in the healthcare sector to ensure that its medications are accessible to patients worldwide. Products: Abstral: a medication for the treatment of acute and chronic severe pain. It is taken sublingually and acts quickly. Zubsolv: a medication for the treatment of opioid addiction. It contains the active ingredients buprenorphine and naloxone and can alleviate withdrawal symptoms in opioid addiction. Edluar: a sleep medication for the treatment of sleep disorders. It contains the active ingredient zolpidem and is taken sublingually. Orexo Digital: an app to support patients in the treatment of pain and addiction disorders. It enables the monitoring of treatment progress and provides helpful advice for improving treatment success. Conclusion: Orexo is an innovative pharmaceutical company specializing in the development of medications for the treatment of pain and addiction disorders. The company has made a name for itself with its unique opioid technology and offers successful products such as Abstral and Zubsolv. With its expansion into the field of digital therapeutics, Orexo also demonstrates that it remains at the forefront of technology and innovation. Orexo ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Orexo's Liabilities

Orexo's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Orexo's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Orexo's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Orexo's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Orexo’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Orexo stock

What is the level of liabilities of Orexo this year?

Orexo has a debt balance of 727.7 M SEK this year.

What were the liabilities of Orexo compared to the previous year?

The liabilities of Orexo have increased by -20.48% dropped compared to the previous year.

What are the consequences of high debt for investors of Orexo?

High liabilities can pose a risk for investors of Orexo, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Orexo?

Low liabilities mean that Orexo has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Orexo affect the company?

An increase in liabilities of Orexo can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Orexo affect the company?

A decrease in the liabilities of Orexo can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Orexo?

Some factors that can influence the liabilities of Orexo include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Orexo so important for investors?

The liabilities of Orexo are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Orexo take to modify the liabilities?

To change its liabilities, Orexo can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Orexo pay?

Over the past 12 months, Orexo paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orexo is expected to pay a dividend of 0 SEK.

What is the dividend yield of Orexo?

The current dividend yield of Orexo is .

When does Orexo pay dividends?

Orexo pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orexo?

Orexo paid dividends every year for the past 0 years.

What is the dividend of Orexo?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orexo located?

Orexo is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orexo kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orexo from 1/2/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 1/2/2025.

When did Orexo pay the last dividend?

The last dividend was paid out on 1/2/2025.

What was the dividend of Orexo in the year 2024?

In the year 2024, Orexo distributed 0 SEK as dividends.

In which currency does Orexo pay out the dividend?

The dividends of Orexo are distributed in SEK.